Sym 021

Drug Profile

Sym 021

Alternative Names: Sym021

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symphogen
  • Class Antibodies; Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lymphoma; Solid tumours

Most Recent Events

  • 17 Oct 2017 Preclinical trials in Lymphoma in Denmark (IV) (NCT03311412)
  • 17 Oct 2017 Preclinical trials in Solid tumours in Denmark (IV) (NCT03311412)
  • 17 Oct 2017 Symphogen plans a phase I trial for Solid tumours and Lymphoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy) in USA and Canada (NCT03311412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top